How estrogen receptor-positive breast cancer responds to hormone therapy may hold keys to understanding how it will respond to radiation therapy, and an experimental drug that increases the effectiveness of hormone therapy also overcomes radiation resistance in breast cancer, a study by UT Southwestern Medical Center researchers shows.
Research from the University of Wisconsin indicates that for patients with breast cancer, the cancer’s stage and receptor status can help clinicians predict whether and when cancer might recur after initial treatment.
Despite racial and ethnic minority groups making up nearly half of the United States population, underrepresentation in clinical trials remains a critical challenge. In an effort to improve clinical trial diversity, researchers at The Ohio State University Wexner Medical Center and College of Medicine partnered with The African American Male Wellness Agency, Genentech Inc., and Pfizer, Inc. to engage with almost 450 community members in 25 states and five countries to create solutions to barriers of access, awareness, discrimination and racism, and workforce diversity.
A study found that recent increases in Medicare spending on outpatient cancer care at the end of patients’ lives were driven almost entirely by a type of treatment given to fewer than 1 in 5 patients.
Genetic counseling and genetic testing for mutations in certain genes—e.g., BRCA1 and BRCA2—can help people understand their risk of certain types of cancer that can run in families, and improve outcomes through prevention, early detection, and targeted treatments, a study conducted at Rutgers Cancer Institutes found.
Scientists at VCU Massey Cancer Center discovered a previously unrecognized relationship between two sets of proteins that operate in tandem to fend off the growth of pancreatic cancer. The findings could provide information for the development of novel therapies for what is currently an incurable disease.
Lucem Health established an early disease detection solution, Lucem Health Reveal, which leverages existing EHR data to identify patients who may be at a higher risk of serious or chronic disease.
Leal Health, formerly known as Trialjectory, presented data on the negative impact of Eastern Cooperative Oncology Group, or ECOG, performance status scores on cancer patients’ eligibility to enroll in clinical trials at the American Society of Clinical Oncology Genitourinary Cancers Symposium.
The phase III SIERRA trial of iomab-B in patients age 55 and above with active relapsed or refractory acute myeloid leukemia, led by Actinium Pharmaceuticals Inc., showed positive results in its primary and secondary endpoints.
Results from the pivotal phase III KEYNOTE-859 trial showed that Keytruda (pembrolizumab) plus chemotherapy significantly improved overall survival for patients with human epidermal growth factor receptor 2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, regardless of PD-L1 expression.
